SHIFTING THE PARADIGM
mimiX is a biomedical company based in Switzerland. Our proprietary tissue production technology – Sound Induced Morphogenesis – was developed as a result of 10+ years of research and development efforts.
Our lead product in development is in the area of personalized medicine – FastSkin®, an autologous tissue for complex wound care. Future areas of interest include: regenerative medicine (neuroscience, cardiovascular, orthopaedics), drug development, cellular agriculture (clean meat), process technology and performance materials.
We target strategic discovery partnerships through industry and academic alliances.
Board of Directors
Leti McManus, CFA
Small cap investment, banking, corporate strategy
mimiX founder & serial entrepreneur
Dr. André Kobelt
« mimiX’s platform combines all the advantages of classical bioprinting upgraded to a new dimension. It is the beginning of a new era of bio fabrication and will help solve humans greatest healthcare challenges »
Andrew Williamson - President Heraeus Medical
Simulation & Physics